Shana Novak | Stone | Getty Images President Donald Trump‘s steep tariffs on Canada, Mexico and China could worsen existing drug shortages in the U.S., raise health-care costs for patients and threaten cash-strapped generic drugmakers, some drug trade groups warn. Trump on Saturday announced he would impose a 25% tariff on nearly all goods shipped…
The Food and Drug Administration on Thursday approved Vertex Pharmaceuticals‘ non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. Vertex is now the first drugmaker in decades to gain U.S. approval for a new type of pain medicine. It’s a milestone after a long history of mostly unsuccessful…
U.S. President Donald Trump speaks about prescription drug prices during an appearance in the Brady Press Briefing Room at the White House in Washington, U.S., November 20, 2020. Carlos Barria | Reuters Pharmaceutical companies appear to be hopeful about their growth under a Trump administration, after former President Joe Biden took a hardline stance on…
This photo provided by Janssen Global Services shows Spravato nasal spray. Janssen Global Services via AP The Food and Drug Administration on Tuesday approved Johnson & Johnson‘s nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato,…
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. George Frey | Reuters The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off the second phase of a landmark process that aims…
Most Medicare patients who hit the new $2,000 cap on out-of-pocket spending for prescription drugs could see massive savings, despite changes in premiums, according to a report released Thursday by AARP. The findings suggest the cap could be a huge benefit to older adults in Medicare who struggle to afford high-cost drugs for cancer, rheumatoid…
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In…
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s…
The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio. Moderna now…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. That opens the door for broader access to Zepbound, which is…
